Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds

NCT ID: NCT07312513

Last Updated: 2025-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-09

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this post market clinical follow up (PMCF) study is to confirm the performance of Debrisoft® Duo, to collect safety data regarding expected adverse events and to detect potential unexpected adverse events associated with the use of Debrisoft® Duo within the certified indications and under the conditions of routine use.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical investigation will be conducted as multicenter, randomized in parallel groups, non-inferiority controlled trial. After randomization patients will receive wound debrided with the investigational device or the comparator device during one study visit. During the study visit patients will have clinical examination and wound photos will be taken.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Ulcers Arterial Ulcers Venous Ulcers Pressure Ulcers Postoperative Wounds Healing by Secondary Intention Burns and Scalds Epidermolysis Bullosa (EB) Traumatic Wounds Surgical Wounds

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Debridement mechanical debridement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Debrisoft Duo

Patients will be treated with the investigational device which is a two sided pad for the debridement of a wide range of wounds. The soft, wide side of the device is identical to the comparator device. The textured, beige side is unique to the investigational device and makes it easy to loosen strongly adherent, fibrinous wound debris.

Group Type EXPERIMENTAL

two sided debridement pad

Intervention Type DEVICE

two sided debridement pad

Debrisoft Pad

Patients will be treated with the comparator device which is a one sided pad for the debridement of a wide range of wounds. The device has the same soft, wide side as the investigational product but does not have the aditional textured, beige side.

Group Type ACTIVE_COMPARATOR

one sided debridment pad

Intervention Type DEVICE

one sided debridment pad

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

two sided debridement pad

two sided debridement pad

Intervention Type DEVICE

one sided debridment pad

one sided debridment pad

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Patient is legally capable
* Patient has signed written informed consent
* Presence of one of the following wounds

* Venous lower leg ulcer
* Arterial ulcer
* Diabetic ulcer
* Pressure ulcer
* Post-operative wound healing by secondary intention
* Traumatic wound
* Surgical wound
* Burn or scald (grade III: after surgical debridement)
* Epidermolysis Bullosa
* Wound area \>4cm2
* The entire wound area can be displayed on one photo from a distance of 25-30 cm
* Covered with at least 30% debris, necrosis, slough, fibrotic tissue

Exclusion Criteria

* Known allergy and/or hypersensitivity to Debrisoft® Duo or any of the product components
* Pregnancy or breast feeding
* Patient is illiterate
* Participation in a interventional clinical trial within the last 14 days and during participation in this study
* Any other medical condition, which, by opinion of the investigator, may have impact of the success of the study treatment and/ or interpretation of the study results
* severe pain or hyperesthesia in the wound area
* history of drug or alcohol abuse
* chronic analgesic use (especially opioids) that could influence baseline pain perception
* cognitive impairment, which may affect the ability to accurately self-report pain
* Use of anaesthesia before the debridment procedure
* presence of hard necrotic tissue or other tissue which should not be debrided in general. Other types of hard necrotic tissue requiring debridement, as determined by the investigator, are permitted and may be also pre-moistened before the procedure if deemed necessary
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lohmann & Rauscher

INDUSTRY

Sponsor Role lead

AXCELLANT

UNKNOWN

Sponsor Role collaborator

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MelissaMed Poradnia

Lodz, , Poland

Site Status RECRUITING

MIKOMED Sp. z.o.o.

Lodz, , Poland

Site Status RECRUITING

NZOZ Neuromed M. i M. Nastaj

Lublin, , Poland

Site Status RECRUITING

Specjalistyczny Osrodek Leczniczo Badawczy

Ostróda, , Poland

Site Status RECRUITING

Lecran - Centrum Opieki Nad Ranami-Kunickiego

Wroclaw, , Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Claudia Feldkamp

Role: CONTACT

Phone: +49 2631 99 7910

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-03

Identifier Type: -

Identifier Source: org_study_id